The Protect II study has reported positive results of the Impella 2.5 device, designed to enhance blood circulation and support blood pressure in high-risk patients undergoing percutaneous coronary intervention compared to the standard treatment, an intra-aortic balloon pump.
Impella is small enough to be inserted like a catheter, through the groin to the heart, and works by decreasing the heart’s workload and increasing blood pressure.
The study, which enrolled 447 patients with severe coronary artery disease and decreased heart pumping capacity, showed the clinical benefits for patients undergoing high-risk percutaneous coronary intervention without atherectomy.
Related
Related Companies
